Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Trulicity

Trulicity 0.75 mg solution for injection in pre-filled pen Trulicity 1.5 mg solution for injection in pre-filled pen Trulicity 3 mg solution for injection in pre-filled pen Trulicity 4.5 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 8–9

HOS-130065 · Präparat HOS-096833

8  Nervous system Dysgeusia disorders Gastrointestinal Nausea, Decreased Acute Non- disorders diarrhoea, appetite, pancreatitis, mechanical vomiting†, dyspepsia, delayed intestinal abdominal pain† constipation, gastric obstruction flatulence, emptying abdominal distention, gastroesophageal reflux disease, eructation Hepatobiliary Cholelithiasis, disorders cholecystitis Skin and Angioedema# subcutaneous tissue disorders General Fatigue Injection site disorders and reactions$ administration site conditions Investigations Sinus tachycardia, first degree atrioventricular block (AVB) # From post-marketing reports. * Documented, symptomatic hypoglycaemia with blood glucose ≤ 3.9 mmol/L † For dulaglutide 0.75 mg, adverse reaction met frequency for next lower incidence grouping. $ The frequency seen in a paediatric study was common; 3.9 % (2 patients) in the dulaglutide 0.75 mg group, 3.8 % (2 patients) in the dulaglutide 1.5 mg group and 2 % (1 patient) in the placebo group. All events were mild to moderate in severity.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.